Notable Publications
2016
-
Journal of Neuro-Oncology
A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma
Weathers SP, Han X, Liu DD, Conrad CA, Gilbert MR, Loghin ME, O'Brien BJ, Penas-Prado M, Puduvalli VK, Tremont-Lukats I, Colen RR, Yung WKA, de Groot JF
-
Molecular Cancer Therapeutics
Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models
Park SY, Piao Y, Jeong KJ, Dong J, de Groot JF
-
Neuro-Oncology
Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models
Piao Y, Park SY, Henry V, Smith BD, Tiao N, Flynn DL, de Groot JF
-
Journal of Neuro-Oncology
Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma
Mandel JJ, Cachia D, Liu D, Wilson C, Aldape K, Fuller G, de Groot JF
2014
-
Clinical Cancer Research
Antiangiogenic therapy for glioblastoma: current status and future prospects
Batchelor TT, Reardon DA, de Groot JF, Wick W, Weller M
-
PLOS One
Molecular subtypes of glioblastoma are relevant to lower grade glioma
Guan X, Vengoechea J, Zheng S, Sloan AE, Chen Y, Brat DJ, O'Neill BP, de Groot J, Yust-Katz S, Yung WK, Cohen ML, Aldape KD, Rosenfeld S, Verhaak RG, Barnholtz-Sloan JS
2013
-
Journal of Clinical Oncology
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma
Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, Degroot J, Gattamaneni R, Cher L, Rosenthal M, Payer F, Jürgensmeier JM, Jain RK, Sorensen AG, Xu J, Liu Q, van den Bent M
-
Targeted Oncology
Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept
Shonka N, Piao Y, Gilbert M, Yung A, Chang S, DeAngelis LM, Lassman AB, Liu J, Cloughesy T, Robins HI, Lloyd R, Chen A, Prados M, Wen PY, Heymach J, de Groot J
2012
-
Neuro-Oncology
Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype
Piao Y, Liang J, Holmes L, Zurita AJ, Henry V, Heymach JV, de Groot JF
-
Neurology
Moving toward molecular classification of diffuse gliomas in adults
Theeler BJ, Yung WK, Fuller GN, De Groot JF
2011
-
Clinical Cancer Research
High-dose antiangiogenic therapy for glioblastoma: less may be more?
de Groot JF
-
Oncotarget
Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma
de Groot J, Liang J, Kong LY, Wei J, Piao Y, Fuller G, Qiao W, Heimberger AB
-
Journal of Clinical Oncology
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study
de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, Deangelis LM, Yung WK, Chen A, Prados MD, Wen PY
-
Clinical Cancer Research
Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept
de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, DeAngelis L, Camphausen K, Chen A, Yung WK, Prados M, Wen PY, Heymach JV
-
Journal of the National Comprehensive Cancer Network
Multigene sets for clinical application in glioma
de Groot JF, Sulman EP, Aldape KD
-
Neuro-Oncology
Clinical trial end points for high-grade glioma: the evolving landscape
Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, Van den Bent MJ, Wen PY
2010
-
Neuro-Oncology
Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice
de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, Conrad CA
-
Journal of Clinical Oncology
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group
Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM
2009
-
Clinical Cancer Research
Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy
Lucio-Eterovic AK, Piao Y, de Groot JF
-
Molecular Cancer Therapeutics
Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma
Milano V, Piao Y, LaFortune T, de Groot J